TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
NEW ORLEANS, Aug. 01, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against IntelliPharmaCeutics International, Inc. (NasdaqCM:IPCI), if they purchased the Company’s shares between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased shares of IntelliPharmaCeutics and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nasdaqcm-ipci/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by September 29, 2017.
About the Lawsuit
IntelliPharmaCeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company failed to perform human abuse testing to support the New Drug Application (“NDA”) for Rexista; (ii) the Company failed to include studies conducted to support Rexista’s label claims regarding human abuse by various pathways; (iii) the Company was not submitting data to sufficiently support approval of the NDA; and (iv) as a result of the foregoing, IntelliPharmaCeutics’ financial statements were materially false and misleading at all relevant times.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
